The clinical trial included 74 SCLC patients whose cancer had progressed after at least one course of treatment. Of the 60 study participants treated with Rova-T doses in the active range of 0.2 to 0.4 mg/kg, 68 percent achieved disease stabilization and 18 percent experienced confirmed reductions in tumor sized.
“The goal is always to give the right patient the right drug at the right time, but patients with advanced small cell lung cancer have not benefited from any of the new targeted therapies available to patients with other types of cancer,” said Charles M. Rudin, MD, PhD, chief of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in New York.
SCLC is aggressive and accounts for about 15 percent of all instances of lung cancer. Two-thirds of SCLC patients are found to have extensive stages of the disease upon diagnosis. The survival rate for these patients is typically less than one year.
More articles on quality:
Children’s hospitals push to improve sleep for patients
Prevention key to reducing racial disparities among stroke victims, study suggests
PDI Healthcare announces new product demos at APIC 2016
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
